Cargando…
Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer
Podocalyxin overexpression associates with poor survival in pancreatic cancer (PDAC). We investigated whether podocalyxin expression correlates with treatment response or survival in neoadjuvant-treated PDAC. Through immunohistochemistry, we evaluated podocalyxin expression in 88 neoadjuvant and 143...
Autores principales: | Eurola, Annika, Ristimäki, Ari, Mustonen, Harri, Nurmi, Anna-Maria, Hagström, Jaana, Haglund, Caj, Seppänen, Hanna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110523/ https://www.ncbi.nlm.nih.gov/pubmed/33972616 http://dx.doi.org/10.1038/s41598-021-89134-2 |
Ejemplares similares
-
Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma
por: Saukkonen, Kapo, et al.
Publicado: (2015) -
The expression and prognostic value of toll-like receptors (TLRs) in pancreatic cancer patients treated with neoadjuvant therapy
por: Nurmi, Anna Maria, et al.
Publicado: (2022) -
Podocalyxin is a marker of poor prognosis in colorectal cancer
por: Kaprio, Tuomas, et al.
Publicado: (2014) -
Preoperative oncologic therapy and the prolonged risk of venous thromboembolism in resectable pancreatic cancer
por: Eurola, Annika, et al.
Publicado: (2022) -
Podocalyxin as a Prognostic Marker in Gastric Cancer
por: Laitinen, Alli, et al.
Publicado: (2015)